Benzinga | Jul 27, 2020 08:35AM EDT

Amyris And The Infectious Disease Research Institute Sign Binding Term Sheet For Planned COVID-19 RNA Vaccine Technology Program

EMERYVILLE, Calif., July 27, 2020 /PRNewswire/ --Amyris, Inc. (NASDAQ:AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets and IDRI (Infectious Disease Research Institute) today announce the signing of a binding term sheet for a planned COVID-19 RNA (ribonucleic acid) vaccine technology program. The program combines IDRI's expertise in combating infectious diseases with Amyris' fermentation platform technology, with the goal to create semi-synthetic squalene-based adjuvants at scale. IDRI's RNA vaccine platform is expected to offer significant differentiated advantages over other RNA vaccines currently in development and will be further enhanced by a scalable Amyris adjuvant.